Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

Jason Harris
Published: Friday, Jan 25, 2019
Gwen L. Nichols, MD

Gwen L. Nichols, MD

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment, according to a study commissioned by the Leukemia & Lymphoma Society (LLS).1


On average, per-patient spending in the first year after diagnosis topped 6,000, according to the Milliman research company, which conducted the study. The per-patient average ranged from nearly ,000 for chronic leukemia to more than 0,000 for acute leukemia (Figure).1 The figures in the report represent allowed spending, defined as costs paid by payers and patients combined, not including expenses not covered by insurance. Most of these costs are covered by payers, the report noted.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication